Nilogen To Present At AACR 2023

Apr 07, 2023

Posted by Nilogen Oncosystems

Nilogen will present four posters at the upcoming AACR conference in Orlando from April 14th to April 19th. Come visit the Nilogen team at booth #1700 or any of our posters presented on April 18th to learn about the transformative impact of using fresh patient tumor tissue in oncology drug development and biomarker discovery.

If you would like to schedule a meeting to discuss in detail please use the link below, or contact Jeremiah Treanor directly at

Schedule A Meeting

Booth Number: 1700


Poster Session: 3D & Tissue Recombinant Models 

Date: Tuesday April 18th, 1:30-5:00pm


Poster Details:

4552: 3D-EXplore Platform of Fresh Patient Tumoroids with Intact TME Allows Assessment of the Efficacy of Drugs Targeting the Tumour Stroma on Tumour Immunotherapy ex vivo.

Cancer associated fibroblasts (CAFs) are a major component of the tumour microenvironment (TME) and exhibit diverse tumorigenic functions such as immunosuppression and extracellular matrix (ECM) remodelling. Treatment of solid tumours is often hindered by a complex TME, which persists despite effective tumour cell directed therapies. Therefore, treatment of solid tumours in combination with stromal targeting therapies is essential to overcome CAF facilitated tumour growth, and immunosuppression. Herein we interrogate the impact of tumour stroma targeting therapeutics, in combination with nivolumab, on the efficacy of tumour cell killing (TCK) in a 3D human tumoroid ex vivo culture platform.

4557: 3D-EXpress Platform Utilizing Tumoroids from Patients with MSS and MSI-H Tumors Allows Rapid Assessment of Anti-Tumour Activity of Immune Checkpoint Inhibitors and Development of Clinically Relevant Biomarkers of Treatment Response.

Recent studies have shown that patients with deficient mismatch repair (dMMR) and microsatellite instability-high (MSI-H), have higher sensitivity to immune checkpoint inhibitors (ICIs) compared to patients with microsatellite-stable (MSS) microsatellite instability-low (MSI-L). However, the mechanisms of treatment responsiveness and resistance is not well understood. Here, we used a novel 3D-EXpress ex vivo fresh patient tumoroid platform to assess the efficacy of nivolumab and Ipilimumab combination therapy in tumours with known MSS and MSI-H status and performed correlative studies.

4571: A Novel ex vivo Platform, 3D-EXpress, to rapidly assess the efficacy of KRAS targeting Drugs alone and in Combination with Nivolumab using a Biorepository of Fresh Patient Tumoroids with Intact Tumour Microenvironment. 

Nilogen tumoroids retain tumour cell heterogeneity, tumour resident innate and adaptive immune cells, stromal and extracellular matrix interaction allowing you to rapidly test the efficacy of your therapeutic approach. Here we employed the 3D-EXpress platform to compare the efficacy of different drugs and drug combinations targeting KRAS and PD-1/PD-L1 immune checkpoint ex vivo.

4572: 3D-EXpress ex vivo Platform using a Biorepository of Characterized Fresh Patient Tumoroids allows Development of Rational Combinations with drugs Targeting DNA Damage Response and Immune Checkpoint Blockade. 

The 3D-EXpress platform employed here provides detailed observations investigating tumour cell viability using confocal microscopy and immune cell activation indicated by increases in cytokine release.

See all Member News